BDS-1000 Dossier: Johnson & Johnson

Target Profile

Factbox:

• Founded 1886 in New Brunswick, New Jersey
• 2023 spinoff of consumer health division as Kenvue Inc.
• Approximately 1,000+ employees across four Israeli subsidiaries
• Acquired Omrix Biopharmaceuticals (2008), Biosense Webster (1998), V-Wave (2024)
• JLabs Tel Aviv and Jerusalem incubators; FutuRx partnership

Executive Summary

Johnson & Johnson is a global pharmaceutical and medical technology corporation with documented operational presence in Israel through six active subsidiaries, including J-C Health Care Ltd., Omrix Biopharmaceuticals Ltd., and Biosense Webster (Israel) Ltd. The company’s Israeli footprint encompasses R&D facilities, manufacturing operations, and innovation ecosystem participation through JLabs and the FutuRx biotechnology incubator.

The V-MIL audit found no verified defence contracts, weapons system involvement, or direct supply relationships with Israeli military or security forces. While J&J operates a blood bank at Sheba Medical Center (a military/combat trauma centre) until 2021, no evidence of ongoing logistical support to IDF bases was identified. The company’s board includes individuals with defence-sector backgrounds—Marillyn A. Hewson (former Lockheed Martin CEO) and Dr. Nadja West (retired U.S. Army Lieutenant General)—but no evidence links these connections to Israeli defence supply.

The V-DIG audit identified no digital or technology relationships with Israeli surveillance, cybersecurity, or intelligence entities. The V-ECON audit documented substantial economic activity: acquisitions of Israeli companies, R&D operations, and participation in government-funded innovation incubators. The V-POL audit found limited political engagement—$2 million in post-October 7 humanitarian donations, but no conflict-specific statements, no identified BDS-targeting beyond commercial operations, and no documented lobbying on Israel-specific legislation.

The resulting BRS score of 484 places Johnson & Johnson in Tier C (High), driven primarily by economic activity (V-ECON: 7.50) while military, digital, and political vectors remain minimally evidenced. The company is not listed in the UN OHCHR settlement database, the PAX “Companies Arming Israel” report, or the Who Profits database of occupation-linked companies.

Timeline of Relevant Events

Corporate Overview

Structure and Subsidiaries

Johnson & Johnson operates through three primary segments following the 2023 Kenvue spinoff: Innovative Medicine (pharmaceuticals), MedTech (medical devices), and (historically) Consumer Health. The company’s Israeli subsidiary structure includes:

• J-C Health Care Ltd. — Operating entity for Janssen Israel, based in Shefayim (Kibbutz) ¹¹⁰
• Omrix Biopharmaceuticals Ltd. — Biosurgical and immunotherapy products, Har Hotzvim Technology Park, West Jerusalem ¹¹
• Biosense Webster (Israel) Ltd. — Global R&D and manufacturing technology centre, Yokneam ¹²¹³
• J&J MedTech Israel — Engineering/R&D office, Yokneam ¹²
• JLABS @ Jerusalem — Life sciences incubator, opened 2019 ¹⁴
• FutuRx Biopharma Incubator — Partnered with Israel Innovation Authority, Weizmann Science Park, Rehovot ¹⁴¹⁵

Israeli Entity Relationships

J&J participates in the Israeli innovation ecosystem through multiple channels: direct R&D operations, corporate venture investment (JJDC), and public-private incubator partnerships. The JLabs Tel Aviv and JLabs @ Jerusalem facilities were established with support from the Israel Innovation Authority (formerly Office of Chief Scientist), which provided approximately $2 million in government funding ⁶¹⁶. The FutuRx incubator involves collaboration with the Israel Innovation Authority, indicating state-linked benefits for the innovation ecosystem ¹⁴¹⁵.

No evidence was identified of J&J operating facilities within Israeli settlements in the occupied West Bank or East Jerusalem ⁸¹⁷.

Domain Summaries

V-MIL: Military

Mechanism of Involvement

Johnson & Johnson’s military involvement vector is minimal. The company maintains six subsidiaries in Israel but operates exclusively in pharmaceutical, medical device, and biotechnology sectors. No verified contracts, tender awards, or memoranda of understanding between J&J (or its subsidiaries) and Israeli Ministry of Defence, Israel Defence Forces, Israel Prison Service, or Israel Border Police for defence equipment, weapons systems, or security infrastructure have been identified in public records ¹⁷¹⁸.

Through subsidiary Omrix Biopharmaceuticals, J&J manufactures plasma-derived immunoglobulins including Vaccinia Immune Globulin (VIG/VIGIV), a dual-use biodefense product with both civilian and military/biodefense applications. No public evidence identifies any direct IDF or Israeli Ministry of Defence procurement contract for these products ¹⁹.

J&J historically operated a blood bank at Sheba Medical Center (Tel Hashomer) until 2021. Sheba is Israel’s largest hospital and serves as a major military/combat trauma centre treating IDF personnel. No verified contracts for catering, transport, fuel supply, waste management, or facilities maintenance to IDF bases have been identified ⁷.

Counter-Arguments and Evidence Limits

J&J does not manufacture heavy machinery, armoured vehicles, or demolition equipment. No evidence places J&J equipment in construction, maintenance, or demolition activity within Israeli settlements, the separation barrier, military installations, or occupied territories. The company is not listed in the UN Human Rights Council database of 158 business enterprises involved in Israeli settlement activity (2020, 2023, 2025 iterations) ¹². J&J does not appear in the PAX “Companies Arming Israel” report, the Who Profits Research Center database, or the American Friends Service Committee “Investigate” database ²⁰¹⁷¹⁸.

No export licence denials, enforcement actions, or legal challenges specifically concerning J&J’s defence supply relationship with Israel have been identified in U.S. DDTC, BIS, or EU/UK export control databases ¹⁸.

Named Entities and Evidence Map

V-DIG: Digital

Mechanism of Involvement

No public evidence identifies Johnson & Johnson holding direct licensing, subscription, or integration relationships with Israeli-origin cybersecurity or enterprise software vendors including CyberArk, Check Point, SentinelOne, Palo Alto Networks, Wiz, Claroty, NICE, or Verint. No evidence confirms deployment of Israeli-origin facial recognition, biometric identification, behavioral analytics, or predictive policing tools.

J&J maintains a strategic partnership with Microsoft (announced January 2022) making Microsoft Azure the preferred cloud provider for digital surgery solutions, using Azure, AI, ML, Azure IoT, and Edge Computing. This partnership is a commercial B2B relationship; no evidence indicates involvement with Israeli state customers ²⁰.

No data centre operations, leasing, or co-locating within Israel has been identified. J&J does not participate in Project Nimbus or comparable Israeli state-backed cloud infrastructure programmes ¹⁹.

Counter-Arguments and Evidence Limits

J&J is a pharmaceutical and medical device company; it does not operate consumer retail stores in formats that typically deploy frictionless checkout or loss-prevention biometric systems. The company’s robotics portfolio (Ottava surgical robot, Monarch bronchoscopy platform) is clinical in application with no autonomous weapons or lethal systems development.

No regulatory inquiries, legal challenges, export control actions, or sanctions-related investigations involving J&J’s technology sales to Israeli state entities have been identified. The UN OHCHR Business Enterprise Database does not contain J&J entries ²¹. The June 2025 UN Special Rapporteur report (A/HRC/59/23) does not specifically name Johnson & Johnson in its company listings ³.

Named Entities and Evidence Map

V-ECON: Economic

Mechanism of Involvement

Johnson & Johnson maintains substantial economic activity in Israel through direct investment, acquisitions, R&D operations, and innovation ecosystem participation:

Acquisitions: Omrix Biopharmaceuticals ($438M, 2008), Biosense Webster (1998), V-Wave ($600M upfront, 2024). The Itamar Medical acquisition in 2021 was incorrectly attributed in some sources—Itamar Medical was acquired by ZOLL Medical (Asahi Kasei) in 2022, not by J&J ²⁷.

Innovation Partnerships: J&J participates in the FutuRx biotechnology incubator near Weizmann Science Park, Rehovot, in partnership with the Israel Innovation Authority, Takeda, and OrbiMed ¹⁴¹⁵. JLabs @ Jerusalem operates in formal partnership with the Jerusalem Municipality ¹⁴.

Operational Footprint: J-C Health Care Ltd. (Shefayim), Omrix Biopharmaceuticals (Har Hotzvim Technology Park, West Jerusalem), Biosense Webster (Yokneam—approximately 600 staff), and J&J MedTech Israel collectively employ over 1,000 people in Israel ¹²²⁰.

Profit Flow: Direction of profit repatriation is outward—from Israeli subsidiaries to the U.S. parent entity. Standard Israeli tax rules apply: 25-30% dividend withholding tax and 10% royalty withholding tax on intercompany flows ²².

Counter-Arguments and Evidence Limits

No evidence identifies J&J holding direct commercial procurement relationships with Israeli agricultural aggregators or exporters. J&J does not sell fresh or packaged produce subject to country-of-origin labeling regulations. No NGO investigation, DEFRA advisory, EU Commission labeling enforcement action, or customs audit finding identifies J&J as a retailer or importer of settlement-origin agricultural products ¹⁸¹⁶.

J&J is not listed in the UN OHCHR Settlement Database of 158 business entities involved in settlement activity ⁸. J&J is not listed in the Who Profits database of companies involved in Israeli occupation ¹⁸. J&J is not listed in PAX “Companies Arming Israel” report ²³. No evidence identifies J&J maintaining accounts with Israeli banks for Israeli operations ²⁴ or treasury investments in Israeli sovereign debt ²⁵.

No Israeli government equity stake, golden share arrangement, or government board appointee has been identified in any reviewed filing ⁴.

Named Entities and Evidence Map

V-POL: Political

Mechanism of Involvement

Johnson & Johnson’s political engagement with the Israel-Palestine context is limited. Following the October 7, 2023 Hamas attacks, J&J made a $2 million humanitarian donation and condemned the attacks while speaking out against antisemitism. No press release specifically named Gaza, Palestine, or described the humanitarian situation beyond this initial response ⁸.

J&J has not issued a named, conflict-specific public statement addressing the Israel-Palestine conflict, Gaza hostilities, or Palestinian civilian harm. This contrasts with J&J’s documented statements on Russia-Ukraine (March 2022—suspension of new business in Russia, humanitarian medicine supply to Ukraine), George Floyd/racial justice (2020—$100 million commitment), and COVID-19 global access (2021) ⁸.

Lobbying: J&J maintains substantial corporate lobbying in the United States ($9–11 million annually, 2020–2023), focused on domestic issues including drug pricing, patent/IP policy, FDA regulation, and tort reform. No evidence identifies registered lobbying activity on Israel-specific legislation, anti-BDS legislation, or U.S.-Israel trade policy in Senate LDA filings ⁴.

Political Contributions: J&J PAC (FEC ID C00010983) contributes across both parties. In the 2023–2024 cycle, the PAC contributed $519,500 total: 45.14% to Democrats ($234,500), 55.44% to Republicans ($288,000). No evidence identifies contributions to FIDF, JNF/KKL, or other parastatal or settlement-linked organizations ⁴¹²²⁰.

Government Partnerships: JLabs Tel Aviv received approximately $2 million in government funding from the Office of Chief Scientist (now Israel Innovation Authority) ⁶¹⁶.

Counter-Arguments and Evidence Limits

No evidence identifies J&J issuing conflict-specific statements, making product donations to IDF, or providing logistics/infrastructure credits to Israeli government or Gaza-related efforts beyond the $2 million humanitarian commitment. This contrasts with J&J’s Ukraine response involving specific named product donations and Russian operation suspension ⁸.

No evidence identifies CEO Joaquin Duato or prior CEO Alex Gorsky making personal donations to FIDF, JNF, Israeli settlement organizations, or named pro-Israel advocacy groups. No evidence identifies board members holding personal leadership roles in FIDF, JNF, AIPAC, or equivalent geopolitical pressure organizations ⁸.

No OECD National Contact Point complaints, formal legal actions, or international body rulings specifically targeting J&J’s territorial operations in occupied Palestinian territory were identified ⁸. J&J is not specifically flagged in the American Friends Service Committee “Investigate” database ¹⁸.

BDS campaigns cite J&J as a boycott target, but the publicly cited grounds are “direct involvement in the Israeli economy” through commercial operations, not defence or military supply. BDS India, BDS Coalition Canada, and Disoccupied.com list J&J under commercial boycott targets ⁸⁵⁴. No pension funds or sovereign wealth funds have divested from J&J specifically citing Israeli defence or settlement activities. Norway’s Government Pension Fund Global exclusion list does not include J&J ²⁷.

Named Entities and Evidence Map

BDS-1000 Score (V4)

• V_MAX: 7.50 Sum_OTHERS: 1.22
• BRS Score: 484 Tier: C (High)

The V_MAX of 7.50 (V-ECON) reflects substantial documented economic activity: acquisitions of Israeli companies, R&D and manufacturing operations employing over 1,000 people, and participation in government-funded innovation incubators. The Sum_OTHERS (1.22) combines minimal military, digital, and political vectors. The resulting BRS score of 484 places Johnson & Johnson in Tier C (High), indicating significant but primarily commercial economic involvement without verified defence, surveillance, or settlement-specific political engagement.

Methodology Note

• Evidence-only framework: All scores derived exclusively from the four domain audits (V-MIL, V-DIG, V-ECON, V-POL). No speculative or unverified claims included.
• Scale-free Impact calculation: Impact (I) measures activity type severity; Magnitude (M) measures scale; Proximity (P) measures directness of involvement.
• Temporal rule: Divested or exited operations (e.g., Sheba blood bank closed 2021) are reflected in reduced scores.
• Entity attribution: No transitive guilt—only direct corporate relationships counted, not those of shareholders, board members, or institutional investors.
• Settlement operation dual-counting: Economic activity in settlement locations counts toward both V-ECON and V-POL; J&J operations are documented in Israeli domestic territory (pre-1967 borders), not settlements.
• “No public evidence identified”: Used where comprehensive checks found no documentation supporting a claim; this is a neutral finding, not a determination of absence.

End Notes